Rad AI announces $4M funding round led by Google’s Gradient Ventures

Rad AI, a Berkeley, California-based healthcare startup focused on bringing AI to radiology, is launching with a $4 million funding round. The round was led by Gradient Ventures, Google’s venture fund dedicated to AI-related investments.

The funds are expected to go toward expanding Rad AI’s engineering team and escalating the rollout of its initial offerings. The company’s first solution was designed to automatically generate a customized “impression” section for radiology reports using machine learning.

“Radiology is facing severe pressures that range from falling reimbursements to market consolidation,” Jeffrey Chang, MD, Rad AI co-founder, said in a prepared statement. “There is also a radiologist shortage that is exacerbated by rising imaging volumes nationwide. We help radiology groups significantly increase productivity, while reducing radiologist burnout and improving report accuracy.”

“The team at Rad AI is uniquely suited to apply innovative technology to this field, with strong radiology and AI experts and firsthand knowledge of this market,” Zachary Bratun-Glennon, partner at Gradient Ventures, said in the same statement. “It's exciting to see the quantitative benefits and positive feedback from their radiology customers, and we're looking forward to the impact of their future products.”

Other investors participating in this round included UP2398, Precursor Ventures, GMO Venture Partners, Array Ventures, Hike Ventures and Fifty Years VC.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.